Clinical Trial Update: Study to Assess the Efficacy and Long-term Safety of Dupilumab (REGN668/SAR231893) in Adult Participants With Moderate-to-Severe Atopic Dermatitis [Phase 3]

View source ↗

Summary

A Phase 3 trial update showing dupilumab demonstrates efficacy and long-term safety in adults with moderate-to-severe atopic dermatitis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• DUPIXENT (DUPILUMAB)

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Atopic Dermatitis | Phase 3 | Status: COMPLETED | Results posted: 2017-10-17